Abacavir, dolutegravir, and lamivudine and Didanosine Delayed-Release Enteric-Coated Capsules

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

The following interaction applies only if you are taking didanosine (Videx) buffered tablet or oral solution and not other didanosine formulations: Taking the dolutegravir and didanosine doses too close together may interfere with the absorption of dolutegravir and reduce its effectiveness in treating HIV infection. To prevent or minimize the interaction, dolutegravir should be taken at least two hours before or six hours after the didanosine dose. Contact your doctor if your condition worsens or you develop new infections during treatment with these medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

ADJUST DOSING INTERVAL: Coadministration with medications containing polyvalent cations such as Al, Ca, Fe, or Mg may decrease the oral bioavailability of dolutegravir. The mechanism of interaction has not been established. In 16 study subjects, administration of a single 50 mg dose of dolutegravir simultaneously with an antacid (Maalox) decreased dolutegravir peak plasma concentration (Cmax), systemic exposure (AUC) and trough plasma concentration (Cmin; 24 hours postdose) by 72%, 74% and 74%, respectively, compared to administration without the antacid. When the antacid was administered 2 hours after dolutegravir, the Cmax, AUC and Cmin of dolutegravir decreased by just 18%, 26% and 30%, respectively. Administration of single-dose dolutegravir simultaneously with a multivitamin (One-A-Day) decreased the Cmax, AUC and Cmin of dolutegravir by 35%, 33% and 32%, respectively.

MANAGEMENT: Dolutegravir should be administered 2 hours before or 6 hours after medications containing polyvalent cations such as antacids, laxatives, or mineral supplements. This also includes didanosine buffered tablets and pediatric oral solution.

Abacavir, dolutegravir, and lamivudine

Generic Name: abacavir / dolutegravir / lamivudine

Brand name: Triumeq

Synonyms: Abacavir, Dolutegravir, and Lamivudine

What is Abacavir, dolutegravir, and lamivudine?

Didanosine Delayed-Release Enteric-Coated Capsules

Generic Name: didanosine

Brand name: Videx, Videx EC

Synonyms: Didanosine

What is Didanosine Delayed-Release Enteric-Coated Capsules?